Access restricted to students and staff of home institution
master's thesis
5   1
TUMORSKI BILJEG CA125 KAO POKAZATELJ PREŽIVLJENJA U BOLESNICA SA ZLOĆUDNIM OVARIJSKIM TUMOROM
Franka Letinić (2012)
University of Split
School of Medicine
Metadata
TitleTUMORSKI BILJEG CA125 KAO POKAZATELJ PREŽIVLJENJA U BOLESNICA SA ZLOĆUDNIM OVARIJSKIM TUMOROM
AuthorFranka Letinić
Mentor(s)Tomislav Strinić (thesis advisor)
Abstract
CILJ ISTRAŽIVANJA: Cilj je odrediti stopu preživljenja u tri skupine bolesnica u odnosu na povišene vrijednosti serumske koncetracije Ca125 u trenutku dijagnoze bolesti. USTROJ ISTRAŽIVANJA: Studija se organizirala kao retrospektivno kohortno istraživanje. Promatrani parametri dob, pripadnost, broj poroda i abortusa, vrsta zloćudnog ovarijskog tumora, stadij po klasifikaciji FIGO, vrsta operativnog zahvata te serumska koncetracija Ca125 u trenutku dijagnoze bolesti dobiveni su uvidom u protokol i arhivu Klinike za ženske bolesti i porode KBC-a Split. MJESTO ISTRAŽIVANJA: Istraživanje je provedeno u Klinici za ženske bolesti i porode Kliničkog bolničkog centra Split, Split, Hrvatska. SUDIONICI: Istraživanjem je obuhvaćeno 50 pacijentica s dijagnozom zloćudnog ovarijskog tumora i povišenim serumskim koncetracijma biljega Ca125. Sve ispitanice podijeljenje su u tri skupine ovisno o klasifikaciji FIGO. GLAVNE MJERE ISHODA: Usporedili smo ukupno preživljenje pacijentica izraženo u mjesecima u odnosu na povišene serumske koncetracije Ca125 markera u trenutku dijagnoze bolesti. REZULTATI: Kaplan-Meier analizom se ispitalo koja je vjerojatnost da sudionici prežive s obzirom na stadij bolesti i vrijednost Ca125 markera. Rezultati analize su pokazali kako ne postoji statistički značajna razlika u Kaplan-Meierovim krivuljama preživljenja između sudionica svakog od stadija (P=0,480; P=0,919; P=0,229). ZAKLJUČAK: Povišena serumska koncentracija tumorskog biljega Ca125 može poslužiti kao jedan od pokazatelja vjerojatnosti ukupnog preživljenja pacijenata. Među tri ispitivane skupine ustanovljeno je da postoji statistički značajna razlika u serumskoj koncentraciji tumorskog biljega CA125. Pokazali smo da serumska koncentracija CA125 korelira s stadijem tumora kao i s životnom dobi pacijentica. Povećanje serumske koncentracije tumorskog biljega Ca125 ne pokazuje statistički značajnu razliku u distribuciji preživljavanja u svakom od stadija ni ukupno među svim sudionicama.
KeywordsOvarian Neoplasms
GranterUniversity of Split
School of Medicine
PlaceSplit
StateCroatia
Scientific field, discipline, subdisciplineBIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Gynecology and Obstetrics
Study programme typeuniversity
Study levelintegrated undergraduate and graduate
Study programmeMedicine
Academic title abbreviationdr. med.
Genremaster's thesis
Language Croatian
Defense date2012
Parallel abstract (English)
OBJECTIVE: The aim is to determine the survival rate in three groups of patients in relation to elevated serum concentrations of CA125 at the time of diagnosis. DESIGN: The study is organized as a retrospective cohort study. The observed parameters of age, background, number of births and abortions, type of malignant ovarian tumors, the classification of FIGO stage, type of surgery and the serum concentration of CA125 at the time of diagnosis were obtained by examining the protocol and the archives of the Department of Gynecology and Obstetrics of Clinical Hospital centre Split. SETTINGS: The research was conducted at the Department of Gynecology and Obstetrics of Clinical Hospital Centre Split in Split, Croatia. PARTICIPANTS: The study included 50 patients diagnosed with malignant ovarian tumors and elevated serum concentration of CA125 marker. All the subjects were divided into three groups depending on the classification of FIGO. MAIN OUTCOME MEASURES: We compared the overall survival of patients in months relative to elevated serum concentrations of CA125 marker at the time of diagnosis. RESULTS: Kaplan-Meier analysis to examine who is likely to survive the participants with regard to disease stage and the value of CA125 marker. Results showed that there was no statistically significant difference in the Kaplan-Meier survival curves between the participants of each stage (P=0,480; P=0,919; P=0,229). CONCLUSION: Elevated serum tumor marker CA125 can serve as a predictor of overall survival of patients. Among the three treatment groups showed a statistically significant difference in serum tumor marker CA125. We have shown that serum CA125 correlated with tumor stage as well as patients age. Increased serum levels of tumor marker CA125 shows no statistically significant difference in survival distribution in each of the stages or the total of all participants.
Parallel keywords (Croatian)Novotvorine jajnika
Resource typetext
Access conditionAccess restricted to students and staff of home institution
Terms of usehttp://rightsstatements.org/vocab/InC/1.0/
URN:NBNhttps://urn.nsk.hr/urn:nbn:hr:171:671169
CommitterLinda Ivas